SCHEMBL5378146

SCHEMBL5378146

CCOC(=O)C(C)(C)SCC#CCOCCc1nc(-c2ccc(C)cc2)oc1C

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 1/20 0.44
PPARA Q07869 10/20 0.42
PPARG P37231 9/20 0.42
PPARD Q03181 3/20 0.42
HSD17B10 Q99714 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41
ALOX15 P16050 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5374650 0.91 HSD17B10 (0.39) TARBP2PPARAPPARGPPARDHSD17B10
SCHEMBL5377994 0.90 PPARA (0.47) PPARAPPARGPPARDHSD17B10ALDH1A1
SCHEMBL5377489 0.87 PPARG (0.37) PPARAPPARGPPARDHSD17B10
SCHEMBL14468366 0.85 TARBP2 (0.48) TARBP2PPARAPPARGPPARDHSD17B10
SCHEMBL5367523 0.83 TARBP2 (0.46) TARBP2PPARAPPARGPPARDHSD17B10
SCHEMBL5367528 0.83 TARBP2 (0.46) TARBP2PPARAPPARGPPARDHSD17B10
SCHEMBL5367857 0.80 PPARG (0.48) PPARAPPARGPPARDHSD17B10ALDH1A1
SCHEMBL5365560 0.79 ALDH1A1 (0.42) TARBP2PPARAPPARGPPARDHSD17B10
SCHEMBL6693789 0.79 SMN1; SMN2 (0.43) TARBP2PPARAPPARGPPARDHSD17B10
SCHEMBL6693786 0.79 SMN1; SMN2 (0.43) TARBP2PPARAPPARGPPARDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-05-06 US claimed
US-6664281-B1 Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators ONO PHARMACEUTICAL CO., LTD. (JP) 2003-12-16 US claimed
EP-1108713-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-06-20 EP claimed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-7241784-B2 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-10 US disclosed
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-05-06 US disclosed
US-6664281-B1 Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators ONO PHARMACEUTICAL CO., LTD. (JP) 2003-12-16 US disclosed
EP-1108713-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087636-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient PPARA, PPARG, PPARD TARBP2 2719/4885PPARA 1/4885PPARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.